(Q45907831)

17 December 2017

reason for preferred rank

title

Soluble IL-2 receptor levels in patients with Graves'ophthalmopathy (English)

1 reference

https://api.crossref.org/works/10.1111/J.1365-2249.1992.TB06462.X

14 October 2022

Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1606722

14 October 2022

1 reference

https://api.crossref.org/works/10.1111/J.1365-2249.1992.TB06462.X

14 October 2022

Graves' ophthalmopathy

1 reference

M. F. Prummel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1606722

14 October 2022

W. M. Wiersinga

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1606722

14 October 2022

R. Van der Gaag

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1606722

14 October 2022

M. P. Mourits

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1606722

14 October 2022

L. Koornneef

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1606722

14 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1606722

14 October 2022

publication date

1 June 1992

1 reference

17 December 2017

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2249.1992.tb06462.x

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1111/J.1365-2249.1992.TB06462.X

https://academic.oup.com/cei/article-pdf/88/3/405/42212823/j.1365-2249.1992.tb06462.x.pdf

14 October 2022

file format

Portable Document Format

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1111/J.1365-2249.1992.TB06462.X

Clinical and Experimental Immunology

14 October 2022

published in

1 reference

17 December 2017

volume

88

1 reference

17 December 2017

issue

3

1 reference

17 December 2017

page(s)

405-409

1 reference

17 December 2017

The soluble interleukin-2 receptor: biology, function, and clinical application

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1992.TB06462.X

Thyroid-associated eye disease: pathophysiology

21 January 2018

1 reference

12 December 2020

Endocrine Ophthalmopathy: Current Ideas Concerning Etiology, Pathogenesis, and Treatment

1 reference

12 December 2020

Management of dysthyroid eye disease

1 reference

12 December 2020

High levels of serum soluble interleukin-2 receptors in hyperthyroid patients: correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism

1 reference

12 December 2020

Dexamethasone inhibits human interleukin 2 but not interleukin 2 receptor gene expression in vitro at the level of nuclear transcription

1 reference

12 December 2020

The effect of carbimazole therapy on interleukin 2, interleukin 2 receptors and free radicals

1 reference

12 December 2020

SERUM SOLUBLE INTERLEUKIN 2 RECEPTOR IN HYPERTHYROID Graves'DISEASE AND EFFECT OF CARBIMAZOLE THERAPY

1 reference

12 December 2020

An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro

1 reference

12 December 2020

Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis

1 reference

12 December 2020

Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy

1 reference

12 December 2020

The pathogenesis of thyroid-associated ophthalmopathy

1 reference

12 December 2020

Circulating monocyte migration inhibitory factor in serum of Graves' ophthalmopathy patients: a parameter for disease activity?

1 reference

12 December 2020

Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus

1 reference

12 December 2020

T lymphocyte activation in euthyroid Graves' ophthalmopathy: soluble interleukin 2 receptor release, cellular interleukin 2 receptor expression and interleukin 2 production

1 reference

12 December 2020

Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach

1 reference

12 December 2020

Serum interleukin-2-receptor in rheumatoid arthritis: a prognostic indicator of disease activity?

1 reference

12 December 2020

Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation

1 reference

12 December 2020

Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition

1 reference

12 December 2020

Therapeutic outcome of prednisone medication and of orbital irradiation in patients with Graves' ophthalmopathy

1 reference

12 December 2020

The pathogenesis and treatment of Graves' ophthalmopathy

1 reference

12 December 2020

Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

1 reference

12 December 2020

Clinical review 13: Diagnosis and management of Graves' ophthalmopathy

1 reference

12 December 2020

The soluble interleukin-2 receptor in rheumatic disease

1 reference

12 December 2020

Serial levels of soluble interleukin 2 receptor in the peripheral blood of patients with rheumatoid arthritis: correlations with disease activity.

1 reference

12 December 2020

Soluble interleukin-2 receptor in sera of patients with Graves' disease

1 reference

12 December 2020

Identifiers

DOI

1 reference

17 December 2017

PMC publication ID

1554494

0 references

1 reference

17 December 2017